IceCure’s Patient-Friendly, Non-Surgical Cancer Treatment
IceCure Medical Ltd. (Nasdaq: ICCM) has published results of an independent study demonstrating safety and efficacy of its ProSense® System. The study, published in the peer-reviewed journal Cancers, demonstrated the safety and efficacy of ProSense® in treating malignant small renal masses.
ProSense is a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal and is approved for the treatment of benign and malignant kidney tumors in the US, Europe, and other countries.
Professor Julien Frandon, Director of the Interventional Radiology Department at Nîmes University Hospital, commented, “We evaluated the safety and efficacy of IceCure’s cryoablation technology for the treatment of renal T1a tumors. This innovative approach has demonstrated remarkable safety profiles, even for challenging and unfavorably located small renal masses. One of the study’s crucial findings is the technology’s ability to preserve renal function post-treatment, which is paramount for patients’ quality of life. This technology stands out as a forward-thinking solution in oncological treatment, providing a combination of patient safety, procedural efficiency, and cost-effectiveness.”
Highlights
The study’s main findings included: Disease-free survival rate was 92% at 26.5 months, recurrent lesions were treated again using cryoablation, achieving a secondary local control rate of 100%, 92.4% of patients were discharged the day after surgery, and no serious adverse events arose.
ProSense® cryoablation is a minimally invasive, non-surgical, outpatient treatment option that destroys tumors by freezing them.
It has been investigated and proven effective in various clinical applications, including breast tumors, kidney cancer, lung cancer, and in palliative care.
Independent and company-sponsored clinical studies of ProSense® have shown strong results, with high rates of tumor destruction, and patient and physician satisfaction.
About IceCure Medical
IceCure Medical (Nasdaq: ICCM) develops and markets ProSense®, an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe, and China.
